Q-omics provides the consensus-scored INTS11 profile across patient tissues and cancer cell-line models. INTS11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INTS11 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, INTS11 protein abundance shows 23,792 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where INTS11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS11 survival associations across molecular data types. INTS11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS11 RNA expression–survival associations across cancer types. High INTS11 expression shows unfavorable associations in ACC, KICH, LGG, LIHC, COAD and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INTS11 RNA expression.
This table summarizes INTS11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for INTS11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS11 shows higher tumor expression in KIRC, COAD, LIHC, BLCA, HNSC and LUAD. The KIRC box plot shows higher INTS11 RNA expression in tumor versus normal tissue (log2 FC = +0.546, t-test p < 0.001).
This table shows molecular features associated with INTS11 in patient tissues and cancer cell lines. In patient samples, INTS11 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
